734 related articles for article (PubMed ID: 16530575)
1. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Braitstein P; Brinkhof MW; Dabis F; Schechter M; Boulle A; Miotti P; Wood R; Laurent C; Sprinz E; Seyler C; Bangsberg DR; Balestre E; Sterne JA; May M; Egger M; ;
Lancet; 2006 Mar; 367(9513):817-24. PubMed ID: 16530575
[TBL] [Abstract][Full Text] [Related]
2. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
May MT; Sterne JA; Costagliola D; Sabin CA; Phillips AN; Justice AC; Dabis F; Gill J; Lundgren J; Hogg RS; de Wolf F; Fätkenheuer G; Staszewski S; d'Arminio Monforte A; Egger M;
Lancet; 2006 Aug; 368(9534):451-8. PubMed ID: 16890831
[TBL] [Abstract][Full Text] [Related]
3. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M
J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
[TBL] [Abstract][Full Text] [Related]
5. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
[TBL] [Abstract][Full Text] [Related]
6. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
[TBL] [Abstract][Full Text] [Related]
7. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries.
Brinkhof MW; Dabis F; Myer L; Bangsberg DR; Boulle A; Nash D; Schechter M; Laurent C; Keiser O; May M; Sprinz E; Egger M; Anglaret X;
Bull World Health Organ; 2008 Jul; 86(7):559-67. PubMed ID: 18670668
[TBL] [Abstract][Full Text] [Related]
8. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
[TBL] [Abstract][Full Text] [Related]
9. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
[TBL] [Abstract][Full Text] [Related]
10. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
11. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.
Keiser O; Orrell C; Egger M; Wood R; Brinkhof MW; Furrer H; van Cutsem G; Ledergerber B; Boulle A;
PLoS Med; 2008 Jul; 5(7):e148. PubMed ID: 18613745
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
13. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
[TBL] [Abstract][Full Text] [Related]
15. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
[TBL] [Abstract][Full Text] [Related]
16. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
Ferradini L; Jeannin A; Pinoges L; Izopet J; Odhiambo D; Mankhambo L; Karungi G; Szumilin E; Balandine S; Fedida G; Carrieri MP; Spire B; Ford N; Tassie JM; Guerin PJ; Brasher C
Lancet; 2006 Apr; 367(9519):1335-42. PubMed ID: 16631912
[TBL] [Abstract][Full Text] [Related]
17. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.
Tuboi SH; Pacheco AG; Harrison LH; Stone RA; May M; Brinkhof MW; Dabis F; Egger M; Nash D; Bangsberg D; Braitstein P; Yiannoutsos CT; Wood R; Sprinz E; Schechter M;
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):70-7. PubMed ID: 20035163
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
; Zwahlen M; Harris R; May M; Hogg R; Costagliola D; de Wolf F; Gill J; Fätkenheuer G; Lewden C; Saag M; Staszewski S; d'Arminio Monforte A; Casabona J; Lampe F; Justice A; von Wyl V; Egger M
Int J Epidemiol; 2009 Dec; 38(6):1624-33. PubMed ID: 19820106
[TBL] [Abstract][Full Text] [Related]
20. Excess mortality and associated factors among people living with HIV initiating highly active antiretroviral therapy in Luzhou, China 2006-2020.
Niu D; Xiao T; Chen Y; Tang H; Chen F; Cai C; Qin Q; Zhao D; Jin Y; Wang S; Hou Y; Lu Z; Yang L; Liu H; Xie D; Zou H; Lyu F
BMC Infect Dis; 2023 Mar; 23(1):186. PubMed ID: 36991355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
